JB Pharma Q2 Profit Surges 16% to Rs 175 cr
By Rediff Money Desk, New Delhi Nov 06, 2024 21:14
JB Chemicals & Pharmaceuticals Ltd reported a 16% increase in profit after tax to Rs 175 crore for the second quarter ended September 2024, driven by strong domestic performance and growth in formulations business.
New Delhi, Nov 6 (PTI) JB Chemicals & Pharmaceuticals Ltd on Wednesday reported a 16 per cent rise in profit after tax to Rs 175 crore for the second quarter ended September 2024.
The company had posted a profit after tax (PAT) of Rs 151 crore in the second quarter of the last fiscal, JB Chemicals & Pharmaceuticals Ltd (JB Pharma) said in a statement.
Its revenue in the second quarter rose 13 per cent to Rs 1,001 crore compared to Rs 882 crore in Q2 FY24, it added.
"JB's domestic business continued to outperform the market, with all our major brands posting strong growth. We have steadily driven strong volume growth for our large brands, including the acquired portfolios," JB Pharma CEO and Wholetime Director Nikhil Chopra said.
On the international front, he said, "Our formulations business performed well in Q2 and CDMO division growth will pick up in H2 as we come out of a seasonally muted Q2".
On the outlook, Chopra said, "We are confident of maintaining this positive traction towards our operating and strategic goals for both this year and beyond. As we chart our future, we remain focused on making the organisation progressive and future-ready".
The company had posted a profit after tax (PAT) of Rs 151 crore in the second quarter of the last fiscal, JB Chemicals & Pharmaceuticals Ltd (JB Pharma) said in a statement.
Its revenue in the second quarter rose 13 per cent to Rs 1,001 crore compared to Rs 882 crore in Q2 FY24, it added.
"JB's domestic business continued to outperform the market, with all our major brands posting strong growth. We have steadily driven strong volume growth for our large brands, including the acquired portfolios," JB Pharma CEO and Wholetime Director Nikhil Chopra said.
On the international front, he said, "Our formulations business performed well in Q2 and CDMO division growth will pick up in H2 as we come out of a seasonally muted Q2".
On the outlook, Chopra said, "We are confident of maintaining this positive traction towards our operating and strategic goals for both this year and beyond. As we chart our future, we remain focused on making the organisation progressive and future-ready".
Source: PTI
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Srestha Finvest
- 0.79 (+ 9.72)
- 60211179
- Thinkink Picturez
- 1.85 (+ 4.52)
- 56806760
- Vodafone Idea L
- 8.12 (+ 0.50)
- 48801033
- GTL Infrastructure
- 2.32 (+ 9.95)
- 37724252
- Standard Capital
- 0.99 (+ 1.02)
- 29317005
MORE NEWS
India-EFTA Trade Pact: Norway Ratification in 2025
Norway plans to ratify the India-EFTA trade agreement in 2025, boosting trade and...
Air India Express Merger Aims for Long-Term...
Air India Express merges with AIX Connect to create a unified budget airline, aiming...
Electronics Component Makers Seek Rs 72,500 Cr...
India's electronics component makers seek a Rs 72,500 crore financial package to boost...